Form 4: CRISPR Therapeutics COO Julianne Bruno Reports Stock Transactions
SEC Form 4 Filing
Julianne Bruno, COO of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On March 20, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, had 3,750 restricted stock units vest, each representing a contingent right to receive one share of CRSP Common Shares.
- Following the vesting, Ms. Bruno sold 1,714 shares on March 21, 2025, at a price of $41.23 per share to cover tax withholding obligations.
- After these transactions, Ms. Bruno directly owns 10,544 common shares and indirectly owns 7,088 common shares through The Julianne Bruno 2022 GRAT.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and is a common occurrence for publicly traded companies like CRISPR Therapeutics. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives, ensuring transparency in insider trading activities.
- The sale of shares to cover tax obligations upon vesting of restricted stock units is a common practice among executives in publicly traded companies.
- Comparable companies such as Editas Medicine and Intellia Therapeutics also have executives who regularly file Form 4s for similar transactions.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to routine executive compensation and tax obligations.
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| March 20, 2024 | Date of grant for the restricted stock unit award covering 15,000 Common Shares. |
| March 20, 2025 | Date of transaction: Vesting of 3,750 restricted stock units. |
| March 20, 2025 | First vesting date for one quarter of the shares from the restricted stock unit award. |
| March 21, 2025 | Date of transaction: Sale of 1,714 shares at $41.23 per share. |
| March 20, 2026 | Second vesting date for one quarter of the shares from the restricted stock unit award. |
| March 20, 2027 | Third vesting date for one quarter of the shares from the restricted stock unit award. |
| March 20, 2028 | Final vesting date for one quarter of the shares from the restricted stock unit award. |
| March 24, 2025 | Date of signature for the Form 4 filing. |
Keywords
CRISPR Therapeutics, CRSP, Julianne Bruno, restricted stock units, Form 4, insider trading, stock sale, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.